Clinical trials: Cholera
Cholera
Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change
Develop a scalable approach for delivering water, sanitation, and hygiene (WASH) messages to households in areas with confirmed cholera patients in Dhaka, Bangladesh.
- Trial name
- CHoBI7 (NCT04816552)
- Testing
- CHoBI7 mHealth program Arm, general message on oral rehydration solution (ORS)
- Where
- Bangladesh
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Diarrhea
A Post-marketing Observational Study of Oral Cholera Vaccine
Chinese survey data indicate that the incidence rate of diarrhea in the general population ranges from 0.17 to 0.70 episodes per person-year, whereas among children under five years of age, the rate is significantly higher…
- Trial name
- NCT07300462
- Testing
- Recombinant subunit B/bacterial cholera vaccine (enteric-coated capsules)
- Where
- 5 sites in China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Shanghai United Cell Biotechnology Co., Ltd
Cholera, Vibrio Cholerae Infection
Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine
Cholera is a life-threatening disease if prompt actions are not taken. The most recent estimates of the global burden of cholera estimate that there are more than 1.3 billion people at risk.
- Trial name
- NCT03373669
- Testing
- Oral Cholera Vaccine, Adjusted Dose Oral Cholera Vaccine
- Where
- Zambia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cholera, Diarrhea
Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)
Objective: The investigators objective is to develop and evaluate the effectiveness of a case area targeted water, sanitation, and hygiene (WASH) intervention in reducing cholera infections and increasing sustained WASH behaviors…
- Trial name
- NCT06003816
- Testing
- Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) CATI, Standard message
- Where
- 2 sites in Bangladesh
- Volunteers
- 3,140 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Typhoid, Cholera
Co-administration Study of OCV, TCV and MR
An open-label, randomized controlled, non-inferiority study of co-administration of OCV, TCV and MR vaccines among children 12 to 59 months of age in Dhaka, Bangladesh will be conducted.
- Conditions
- Typhoid, Cholera, Measles, Rubella
- Trial name
- NCT05771779
- Testing
- Oral Cholera Vaccine (OCV), Typhoid Conjugate Vaccine (TCV), Measles and Rubella (MR)
- Volunteers
- 2,117 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Cholera
Single Dose Azithromycin to Prevent Cholera in Children
This study aims to determine whether single-dose azithromycin is effective in preventing cholera in children who are at extremely high risk of infection.
- Trial name
- NCT04326478
- Testing
- Azithromycin
- Where
- Bangladesh
- Volunteers
- 2,475 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Healthy
To Determine the Safety and Immunogenicity of an Oral Whole Cell ShanChol Cholera Vaccine in Bangladesh
Background: Severe dehydrating cholera due to V. cholerae O1 is an important public health problem in Bangladesh and many other developing countries. V.
- Trial name
- NCT01042951
- Testing
- ShanChol Cholera Vaccine
- Where
- Bangladesh
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Cholera Vaccination
Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya
Background: Despite efforts to control cholera, outbreaks continue to occur in Kenya. Oral cholera vaccines (OCVs) are a critical tool in cholera prevention strategies.
- Trial name
- NCT07487077
- Testing
- Euvichol-S Oral Cholera Vaccine
- Where
- Kenya
- Volunteers
- 1,071 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Cholera Vaccination
Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus
This Phase I/III clinical trial is intended to establish the immunogenicity and safety profile of Biovac OCV-S compared to available WHO pre-qualified vaccine Euvichol®-Plus in healthy adults and children and in adult people…
- Trial name
- NCT07304284
- Testing
- Experimental: Biovac OCV-S (inactivated whole-cell monovalent (O1) oral cholera vaccine), Active Comparator, Euvichol®-Plus
- Where
- 5 sites in South Africa
- Volunteers
- 2,824 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Male Children, 6-24 Months Old With Rotaviral Diarrhoea
Llama Antibody, Rotavirus Diarrhoea, Children
The investigators hypothesize that : oral administration of VHH batch 203027 will be safe and tolerable for healthy Bangladeshi humans of all age groups (Part I) effective in reducing severity of diarrhoea in children with proven…
- Conditions
- Male Children, 6-24 Months Old With Rotaviral Diarrhoea, Non-cholera Patients
- Trial name
- NCT01259765
- Testing
- VHH batch 203027
- Where
- Bangladesh
- Volunteers
- 176 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Vibrio Cholerae, Cholera
Bridging Study for Killed Oral Cholera Vaccine in Ethiopia
This is a randomized, double blind, placebo controlled trial to confirm the safety and determine the immune response of the killed oral cholera vaccine in healthy adults and children in Ethiopia.
- Trial name
- NCT01524640
- Testing
- Killed Bivalent (O1 and O139) whole cell oral cholera vaccine
- Where
- Ethiopia
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Cholera, Diarrhea
Cholera-Hospital-Based-Intervention-for-7-days
The Cholera Hospital Based Intervention for 7 Days (CHoBI7) randomized controlled trial for transition to scale aimed to: (1) Develop and evaluate scalable approaches to integrate the CHoBI7 intervention into the services…
- Conditions
- Cholera, Diarrhea, Stunting
- Trial name
- CHoBI7 (NCT04008134)
- Testing
- CHoBI7 health facility program, CHoBI7 mHealth program, CHoBI7 home visit program
- Volunteers
- 2,626 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cholera
Impact Study of Cholera Vaccination in Endemic Areas - Clinical Surveillance
This project aims to fill this essential knowledge gap by assessing the impact of oral cholera vaccine mass campaigns in 2 sites (urban and rural) in DRC, described in this protocol.
- Trial name
- NCT04853186
- Where
- Democratic Republic of the Congo
- Volunteers
- 6,000 people
- Sponsor
- Epicentre
Cholera
Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence
This project aims to fill this essential knowledge gap by assessing the impact of oral cholera vaccine mass campaigns in 2 sites (urban and rural) in DRC, described in this protocol.
- Trial name
- NCT05829772
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Epicentre
Cholera
Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine
Cholera, a rapidly dehydrating watery diarrheal disease transmitted through water or food contaminated with the bacterium, Vibrio cholerae, is a major cause of morbidity and mortality in low income countries like Bangladesh.
- Trial name
- NCT02823899
- Testing
- HL-OCV, Shanchol
- Where
- Bangladesh
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Safety of the Oral O1 / O139 Cholera Vaccine (Enteric Capsules)
Safety of An Oral O1 / O139 Cholera Vaccine (Enteric Capsules)
Cholera is an acute enteric infectious disease caused by the bacterium Vibrio cholera, leading to watery diarrhea and loss of fluids from the small intestines.
- Trial name
- NCT03237663
- Testing
- The oral O1 / O139 cholera vaccine (enteric capsules)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Cholera, Vibrio Cholerae Infection
Immune Response to a Delayed Second Dose of Oral Cholera Vaccine
Immune response to a delayed second dose of oral cholera vaccine A randomized, controlled, non-inferiority immunogenicity trial in Conakry, The Republic of Guinea
- Trial name
- NCT05453253
- Testing
- Delayed second dose of oral cholera vaccine, Euvichol-Plus, Oral cholera vaccine, Euvichol-Plus, according to manufacturer notice
- Where
- Guinea
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Epicentre
Cholera
Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine
Various field studies has found that the modified , bivalent, whole cell - based oral cholera vaccine (OCV) to be safe, immunogenic and effective with protective efficacy of 67 % in earlier clinical trials.
- Trial name
- NCT01508507
- Where
- India
- Volunteers
- 240 people
- Sponsor
- International Vaccine Institute
Cholera
Oral Cholera Vaccine Delivery in Rural Bangladesh
Background: Vibrio cholerae is one of the major causes of severe diarrheal disease in Bangladesh. It is estimated that there are about 450,000 cholera cases each year in Bangladesh.
- Trial name
- ROCV (NCT01811771)
- Testing
- Shanchol vaccine
- Where
- Bangladesh
- Volunteers
- 60,000 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Cholera
Vaccine- and Infection-derived Correlates of Protection for Cholera
Background: Vibrio cholerae causes millions of cholera cases and thousands of deaths annually. Vaccines are in short supply. There is no agreement on how to introduce new vaccines or evaluate their effectiveness, and the lack of…
- Trial name
- CoP (NCT06455852)
- Testing
- oral cholera vaccine or typhoid conjugate vaccine
- Where
- Bangladesh
- Volunteers
- 1,221 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital